Harmony Biosciences (HRMY) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Harmony Biosciences Revenue Highlights


Latest Revenue (Y)

$582.02M

Latest Revenue (Q)

$186.04M

Harmony Biosciences Revenue by Period


Harmony Biosciences Revenue by Year

DateRevenueChange
2023-12-31$582.02M32.93%
2022-12-31$437.86M43.35%
2021-12-31$305.44M91.21%
2020-12-31$159.74M2564.59%
2019-12-31$6.00M100.00%
2018-12-31--

Harmony Biosciences generated $582.02M in revenue during NA 2023, up 32.93% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Harmony Biosciences Revenue by Quarter

DateRevenueChange
2024-09-30$186.04M7.65%
2024-06-30$172.81M11.77%
2024-03-31$154.62M-8.19%
2023-12-31$168.41M5.08%
2023-09-30$160.27M19.41%
2023-06-30$134.22M12.67%
2023-03-31$119.13M-7.16%
2022-12-31$128.31M9.47%
2022-09-30$117.21M9.51%
2022-06-30$107.03M25.45%
2022-03-31$85.31M-6.47%
2021-12-31$91.21M12.98%
2021-09-30$80.73M9.36%
2021-06-30$73.82M23.71%
2021-03-31$59.67M6.02%
2020-12-31$56.29M23.41%
2020-09-30$45.61M20.01%
2020-06-30$38.01M91.56%
2020-03-31$19.84M230.94%
2019-12-31$6.00M100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--

Harmony Biosciences generated $186.04M in revenue during Q3 2024, up 7.65% compared to the previous quarter, and up 138.61% compared to the same period a year ago.

Harmony Biosciences Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
HRMYHarmony Biosciences$582.02M$186.04M
TVTXTravere Therapeutics$145.24M$62.90M
PTGXProtagonist Therapeutics$60.00M$4.17M
IDYAIDEAYA Biosciences$23.39M-
FENCFennec Pharmaceuticals$21.64M$25.26M
RVMDRevolution Medicines, Inc. Warrant$11.58M-
JANXJanux Therapeutics$8.08M$1.25M
KRONKronos Bio$6.29M$2.69M
PLRXPliant Therapeutics$1.58M-
LYRALyra Therapeutics$1.56M$598.00K
VRDNViridian Therapeutics$314.00K$72.00K
KROSKeros Therapeutics$151.00K$83.00K
GPCRStructure Therapeutics--
NUVLNuvalent--
GOSSGossamer Bio-$95.84M
INZYInozyme Pharma--
VRNAVerona Pharma--
CERECerevel Therapeutics--
REPLReplimune Group--
SNDXSyndax Pharmaceuticals-$3.50M
VTYXVentyx Biosciences--
NVCTNuvectis Pharma--
EWTXEdgewise Therapeutics--

HRMY Revenue FAQ


Harmony Biosciences's yearly revenue for 2023 was $582.02M, representing an increase of 32.93% compared to 2022. The company's yearly revenue for 2022 was $437.86M, representing an increase of 43.35% compared to 2021. HRMY's yearly revenue for 2021 was $305.44M, representing an increase of 91.21% compared to 2020.

Harmony Biosciences's quarterly revenue for Q3 2024 was $186.04M, a 7.65% increase from the previous quarter (Q2 2024), and a 16.08% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $172.81M, a 11.77% increase from the previous quarter (Q1 2024), and a 28.76% increase year-over-year (Q2 2023). HRMY's quarterly revenue for Q1 2024 was $154.62M, a -8.19% decrease from the previous quarter (Q4 2023), and a 29.79% increase year-over-year (Q1 2023).

Harmony Biosciences's revenue growth rate for the last 3 years (2021-2023) was 90.55%, and for the last 5 years (2019-2023) was 9608.46%.